Latest Breaking News On - தேசிய மருத்துவ ப்ராடக்ட்ஸ் சங்கம் - Page 2 : comparemela.com

Published: Feb 03, 2021 By Heather McKenzie Cross-continental drug development and commercialization deals are good for business, and imperative for patients to receive access to the most valuable scientific breakthroughs. This month has already brought a number of these partnerships for the treatment of cancer and other diseases with a significant medical need. Here’s a look at four of them. Illumina and Sequoia Capital China Incubating Genomics Talent On Monday, leading DNA sequencing and array-based technologies company, , announceda deal with global venture capital firm, Sequoia Capital China, to incubate life sciences startups specializing in genomics. Accepted companies will benefit from $500, 000 investment and business guidance and a minimum of $100, 000 prioritizing investments from Sequoia Capital China in the next series of financing, along with access to Illumina’s sequencing systems, reagents, and genomics knowledge.

United statesUnited kingdomSouth koreaAbbvie humiraDenny lanfearJunshi biosciencesGyo sagaraJunshi biosciences coDrug administrationChina national medical products associationDrug developmentCalifornia basedcoherus biosciences incAssociation of southeast asian nationsOno pharmaceutical coSequoia capital china incubating genomicsSequoia capital china